Pragmatica-Lung Study opens for patient enrollment – NCI

The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC). Called the Pragmatica-Lung Study (or S2302), this is one of the first NCI-supported clinical trials to use a trial design that removes many of the barriers that prevent people from joining clinical trials. This “pragmatic” approach aims to increaseContinue…

Click here to continue!

Kashyap Patel, MD, Sees Link Between COVID-19 and Cancer Progression, Calls for More Biomarker Testing

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, sees something different in his practice since the onset of the COVID-19 pandemic—not just with cancer care, but with cancer itself. Since March 2020, the longtime community oncologist has seen multiple patients in his Rock Hill, South Carolina, based-clinic with cholangiocarcinoma, and these patients are developing the rare cancer 20 to 30 years earlier than the typical age at presentation, which is usually 65Continue…

Click here to continue!